US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
US20060258686A1
(en)
*
|
1998-05-29 |
2006-11-16 |
Cheresh David A |
Method of treatment of myocardial infarction
|
JP4865129B2
(ja)
|
1999-01-13 |
2012-02-01 |
ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク |
タンパク質キナーゼ阻害剤を設計するための新規の方法
|
US7223724B1
(en)
*
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
ATE253918T1
(de)
|
1999-12-08 |
2003-11-15 |
Centre Nat Rech Scient |
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
|
NZ518077A
(en)
*
|
2000-08-04 |
2003-11-28 |
Human Genome Sciences Inc |
Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
AU2002252631A1
(en)
*
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
ATE470676T1
(de)
*
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
MXPA05001389A
(es)
|
2002-08-06 |
2005-04-28 |
Astrazeneca Ab |
Piridinas y pirimidinas condensadas con actividad tie2 (tek).
|
CN102558155A
(zh)
|
2003-01-14 |
2012-07-11 |
阿伦纳药品公司 |
作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
|
AU2004221812B2
(en)
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
WO2004100868A2
(en)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
EP2287166A3
(en)
*
|
2003-07-14 |
2011-06-22 |
Arena Pharmaceuticals, Inc. |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
CA2553724A1
(en)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
EP2987796B1
(en)
*
|
2005-02-16 |
2018-08-08 |
Anacor Pharmaceuticals, Inc. |
Halogen-substituted boronophthalides for the treatment of infections
|
US8143285B2
(en)
|
2005-09-06 |
2012-03-27 |
Shionogi & Co., Ltd. |
Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
|
EP2385053B1
(en)
*
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
BRPI0619817B8
(pt)
|
2005-12-13 |
2021-05-25 |
Incyte Corp |
composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
|
EP1981888A4
(en)
*
|
2006-01-13 |
2010-10-13 |
Pharmacyclics Inc |
TYROSINE KINASE INHIBITORS AND USES THEREOF
|
TW200738725A
(en)
*
|
2006-01-25 |
2007-10-16 |
Osi Pharm Inc |
Unsaturated mTOR inhibitors
|
MX2008011220A
(es)
*
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Compuestos de pirazol heterobiciclicos y metodos de uso.
|
DK2004654T3
(da)
*
|
2006-04-04 |
2013-07-22 |
Univ California |
Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
|
WO2007139952A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Method for the preparation of triazole compounds with hsp90 modulating activity
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
WO2008020033A1
(en)
*
|
2006-08-16 |
2008-02-21 |
Action Medicines, S.L. |
Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
|
PL2526771T3
(pl)
|
2006-09-22 |
2017-06-30 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
ES2403546T3
(es)
*
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
US8450336B2
(en)
*
|
2006-12-14 |
2013-05-28 |
Nps Pharmaceuticals, Inc |
Use of D-serine derivatives for the treatment of anxiety disorders
|
ATE528286T1
(de)
|
2006-12-20 |
2011-10-15 |
Bayer Healthcare Llc |
4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
|
AU2007340129B2
(en)
*
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
US9073997B2
(en)
*
|
2007-02-02 |
2015-07-07 |
Vegenics Pty Limited |
Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2008153701A1
(en)
*
|
2007-05-24 |
2008-12-18 |
Schering Corporation |
Compounds for inhibiting ksp kinesin activity
|
MX2009013402A
(es)
|
2007-06-13 |
2010-02-24 |
Incyte Corp |
Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
CA2709879A1
(en)
*
|
2007-12-19 |
2009-06-25 |
The Scripps Research Institute |
Anilides and analogs as rho kinase inhibitors
|
WO2009079008A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Yangbo Feng |
Benzopyrans and analogs as rho kinase inhibitors
|
NZ587051A
(en)
|
2008-01-04 |
2012-12-21 |
Intellikine Llc |
Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8993580B2
(en)
*
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
US8557814B2
(en)
*
|
2008-03-19 |
2013-10-15 |
OSI Pharmaceuticals, LLC |
mTOR inhibitor salt forms
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
NZ590258A
(en)
|
2008-07-08 |
2013-10-25 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
EP2307025B1
(en)
|
2008-07-16 |
2017-09-20 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
CA2738429C
(en)
|
2008-09-26 |
2016-10-25 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
US8697709B2
(en)
|
2008-10-16 |
2014-04-15 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
EP2352501B1
(en)
*
|
2008-11-03 |
2014-01-01 |
ChemoCentryx, Inc. |
Compounds for use in the treatment of osteoporosis
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
BRPI1012159B1
(pt)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
EP2432472B1
(en)
|
2009-05-22 |
2019-10-02 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
EP2467141B1
(en)
|
2009-08-17 |
2018-10-31 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
BR112012007137A2
(pt)
|
2009-09-30 |
2015-09-15 |
Harvard College |
metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
CN105153188B
(zh)
|
2009-10-22 |
2018-06-01 |
法博太科制药有限公司 |
抗纤维化剂的稠环类似物
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
EP4148045A1
(en)
|
2010-01-27 |
2023-03-15 |
Arena Pharmaceuticals, Inc. |
Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
|
AU2011215645A1
(en)
|
2010-02-11 |
2012-09-20 |
Vanderbilt University |
Benzisoxazoles and azabenzisoxazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
EP4036088B1
(en)
|
2010-03-10 |
2024-04-03 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
WO2011133520A1
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
EP3087972A1
(en)
|
2010-05-21 |
2016-11-02 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
JP5892550B2
(ja)
*
|
2010-05-24 |
2016-03-23 |
トーアエイヨー株式会社 |
縮合イミダゾール誘導体
|
EA201890869A3
(ru)
|
2010-06-03 |
2019-03-29 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk)
|
EP2590982B1
(en)
*
|
2010-07-09 |
2017-08-23 |
The Walter and Eliza Hall Institute of Medical Research |
Protein kinase inhibitors and methods of treatment
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
JP5917545B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
AU2012273164B2
(en)
|
2011-06-20 |
2015-05-28 |
Incyte Holdings Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
WO2013006443A2
(en)
|
2011-07-01 |
2013-01-10 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
|
AU2012283775A1
(en)
|
2011-07-13 |
2014-01-23 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
PE20141681A1
(es)
|
2011-07-19 |
2014-11-14 |
Merck Sharp And Dohme B V |
Inhibidores de btk
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
TW201311663A
(zh)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
雜環化合物及其用途
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
WO2013039488A1
(en)
|
2011-09-13 |
2013-03-21 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
EP2773345A1
(en)
|
2011-11-02 |
2014-09-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
WO2013074594A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
DK2780015T3
(en)
|
2011-11-18 |
2017-03-27 |
Heptares Therapeutics Ltd |
M1 MUSCARINRECEPTORAGONISTER
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
CN104080789B
(zh)
*
|
2012-01-31 |
2016-05-11 |
南京奥昭生物科技有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
US9045403B2
(en)
|
2012-02-29 |
2015-06-02 |
Coyote Pharmaceuticals, Inc. |
Geranyl geranyl acetone (GGA) derivatives and compositions thereof
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CA2874211A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Pharmascience Inc. |
Protein kinase inhibitors
|
EP2854859A4
(en)
|
2012-06-04 |
2016-01-13 |
Pharmacyclics Inc |
CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
WO2014018567A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
US9604988B2
(en)
|
2012-07-27 |
2017-03-28 |
Riken |
Agent for treating or inhibiting recurrence of acute myeloid leukemia
|
AU2013323426A1
(en)
|
2012-09-26 |
2015-04-23 |
The Regents Of The University Of California |
Modulation of ire1
|
US9119808B1
(en)
|
2012-10-08 |
2015-09-01 |
Coyote Pharmaceuticals, Inc. |
Treating neurodegenerative diseases with GGA or a derivative thereof
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
*
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
IL291391B
(en)
|
2012-11-15 |
2022-11-01 |
Incyte Holdings Corp |
Sustained release dosage forms of roxolitinib
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
ES2694299T3
(es)
|
2013-02-07 |
2018-12-19 |
Heptares Therapeutics Limited |
Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
PT2964650T
(pt)
|
2013-03-06 |
2019-02-26 |
Incyte Holdings Corp |
Processos e intermediários para a preparação de um inibidor de jak
|
TWI629275B
(zh)
*
|
2013-03-13 |
2018-07-11 |
賽諾菲公司 |
N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
MX2016001639A
(es)
|
2013-08-07 |
2016-10-07 |
Incyte Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
EP3033079B1
(en)
|
2013-08-12 |
2018-10-31 |
Pharmacyclics LLC |
Methods for the treatment of her2 amplified cancer
|
TN2016000094A1
(en)
|
2013-09-30 |
2017-07-05 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase.
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2925944C
(en)
|
2013-10-04 |
2023-01-10 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
CN111265531B
(zh)
|
2013-10-25 |
2023-11-10 |
药品循环有限责任公司 |
治疗和预防移植物抗宿主病的方法
|
CA2931431A1
(en)
|
2013-12-05 |
2015-06-11 |
Acerta Pharma B.V. |
Therapeutic combination of a pi3k inhibitor and a btk inhibitor
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
CN105916859A
(zh)
|
2014-02-03 |
2016-08-31 |
卡迪拉保健有限公司 |
杂环化合物
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
EP3119910A4
(en)
|
2014-03-20 |
2018-02-21 |
Pharmacyclics LLC |
Phospholipase c gamma 2 and resistance associated mutations
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
WO2016019233A1
(en)
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
AU2015300798A1
(en)
|
2014-08-07 |
2017-02-02 |
Pharmacyclics Llc |
Novel formulations of a Bruton's tyrosine kinase inhibitor
|
HUE056329T2
(hu)
|
2014-08-11 |
2022-02-28 |
Acerta Pharma Bv |
BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10196397B2
(en)
|
2014-11-19 |
2019-02-05 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of ibrutinib
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2016106628A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
KR20230151072A
(ko)
|
2015-01-06 |
2023-10-31 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체와 관련된 상태의 치료 방법
|
US10266535B2
(en)
|
2015-01-21 |
2019-04-23 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Inhibitor of FLT3 kinase and use thereof
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
CA3177990A1
(en)
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
|
EP3273966B1
(en)
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
MA41828A
(fr)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
HUE060476T2
(hu)
|
2015-06-22 |
2023-03-28 |
Arena Pharm Inc |
(R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
|
PT3954690T
(pt)
|
2015-07-02 |
2023-06-06 |
Acerta Pharma Bv |
Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida
|
EP3347018B1
(en)
|
2015-09-09 |
2021-09-01 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017048702A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
US10611766B2
(en)
*
|
2015-09-16 |
2020-04-07 |
Loxo Oncology Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
SI3390395T1
(sl)
|
2015-12-16 |
2020-11-30 |
Loxo Oncology, Inc. |
Spojine uporabne kot inhibitorji kinaz
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
IL260691B
(en)
*
|
2016-01-21 |
2022-07-01 |
Zibo Biopolar Changsheng Pharmaceutical Co Ltd |
Burton Tyrosine Kinase Tracers
|
US10435396B2
(en)
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
WO2017156495A1
(en)
|
2016-03-11 |
2017-09-14 |
Corvus Pharmaceuticals, Inc. |
Compounds and methods for modulating bruton's tyrosine kinase
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
AU2017258510A1
(en)
|
2016-04-29 |
2018-10-11 |
Dana-Farber Cancer Institute, Inc. |
HCK as a therapeutic target in MYD88 mutated diseases
|
CN105820184A
(zh)
*
|
2016-05-06 |
2016-08-03 |
蚌埠中实化学技术有限公司 |
一种4-苯氧基苯硼酸的制备方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2017281797A1
(en)
|
2016-06-24 |
2019-01-24 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
SG11201907139UA
(en)
|
2017-02-03 |
2019-09-27 |
Certa Therapeutics Pty Ltd |
Anti-fibrotic compounds
|
EP3582772A1
(en)
|
2017-02-16 |
2019-12-25 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
EP3929194B1
(en)
|
2017-06-01 |
2024-04-17 |
Bristol-Myers Squibb Company |
Substituted nitrogen containing compounds
|
EA202090485A1
(ru)
|
2017-08-14 |
2020-05-27 |
Эпизайм, Инк. |
Способы лечения рака путем ингибирования setd2
|
CN107550905B
(zh)
*
|
2017-09-11 |
2020-07-17 |
浙江永宁药业股份有限公司 |
多取代吡咯并吡啶类化合物的药物用途及其制备方法
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN111699031B
(zh)
*
|
2017-12-27 |
2022-10-28 |
株式会社新生能源研究 |
Co2除去方法和装置
|
EP3737676B1
(en)
|
2018-01-09 |
2024-03-06 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
RS63312B1
(sr)
|
2018-01-30 |
2022-07-29 |
Incyte Corp |
Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
|
MX2020010322A
(es)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
IL310632A
(en)
*
|
2018-08-14 |
2024-04-01 |
Epizyme Inc |
Converted indoles and methods of using them
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
BR112021009106A2
(pt)
|
2018-11-12 |
2021-08-10 |
Debiopharm International S.A. |
compostos antibióticos, métodos de fabricação dos mesmos, composições farmacêuticas que os contêm e seus usos
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
CA3131388A1
(en)
*
|
2019-02-27 |
2020-09-03 |
Richard Keenan |
Pyrazolopyridine compounds for ire1 inhibition
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
SG11202110085TA
(en)
*
|
2019-05-31 |
2021-10-28 |
Sichuan Haisco Pharmaceutical Co Ltd |
Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
WO2021184154A1
(en)
*
|
2020-03-16 |
2021-09-23 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022081512A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
MX2023005747A
(es)
|
2020-11-18 |
2023-07-28 |
Deciphera Pharmaceuticals Llc |
Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
|
CN114751927B
(zh)
*
|
2022-03-08 |
2023-10-31 |
中山大学 |
一种硼酸化合物、制备方法及用途
|
CN115124486A
(zh)
*
|
2022-07-07 |
2022-09-30 |
武汉理工大学 |
苯并噁唑衍生物及其制备方法与应用
|